Videos

In collaboration with the Kidney Cancer Association, CURE® recently hosted the “Educated Patient® Webinar: Treating the Whole Patient: Navigating Kidney Cancer,” hosted by Darlene Dobkowski, Associate Editorial Director for CURE®.

As part of its Speaking Out video series, CURE® spoke with Lisa Carter-Bawa of Hackensack Meridian Health about the role nurses play in helping patients manage treatment side effects.

As part of its Speaking Out video series, CURE® spoke with Upal Basu Roy of LUNGevity about recently approved treatments for lung cancer and what is on the horizon.

As part of its Speaking Out video series, CURE® spoke with Amy C. Moore of LUNGevity about the chemotherapy shortage and its impact on patients with lung cancer.

As part of its Speaking Out video series, CURE® spoke with Amy C. Moore of Lungevity about advancements in treatments for small cell lung cancer.

As part of its Speaking Out video series, CURE® spoke with Brandon Leonard of the LUNGevity Foundation about the role legislation can play in a patient’s cancer journey.

An expert spoke with CURE® about the next steps for patients recently diagnosed with prostate cancer and the types of treatments they may receive.

An expert gives an overview of common endocrine-related side effects that premenopausal women with breast cancer may experience — and what can be done to address them.

Consulting physical therapy early on and speaking up to the health care team can help patients with blood cancer be more prepared for a hematopoietic stem cell transplant, an expert said.

Patients who were obese tended to have an increased risk of moderate to severe GVHD after undergoing allogeneic hematopoietic cell transplantation, research showed.

While posttransplant Xospata did not worsen quality of life in patients with acute myeloid leukemia, it is essential that patients tell their providers about any side effects that they experience, an expert said.

Patients with myeloproliferative neoplasms should keep their care team up to date on any symptoms they’re experiencing, an expert said.

An expert said that he is optimistic about the future use of biomarkers in the kidney cancer space.

There are a few conversations patients should have with their care teams after being diagnosed with bladder cancer — especially as new treatments become more available.

Slower infusion rates of antiemetic drugs may help manage nausea and vomiting in patients with gastric or gastroesophageal junction cancers.

Subcutaneous Opdivo led to similar outcomes to intravenous administration of the drug and may be easier to access down the road, an expert said.

Patients with bladder cancer being treated with the immunotherapy agent, Keytruda, should not hesitate to call their oncology team if something does not feel right, an expert said.

Circulating tumor DNA can be a valuable tool in gastric cancer, but unanswered questions remain, an expert said.

“In my career of almost 30 years, I've never seen a liver cancer patient that did not have a chronic underlying liver disease,” Dr. Mindie H. Nguyen told CURE®.

Older adults with gastric cancer tended to have better outcomes when they walked 2,500 steps per day or more.

The use of FOLFOXIRI for metastatic colorectal cancer was lower than one what expert was expecting.

Patients with myelofibrosis should reflect on their personal priorities and quality of life goals, understand the range of available JAK inhibitor treatment options, and openly communicate with their doctor to arrive at a shared decision for managing their disease.

When it comes to bladder cancer, it’s important to note the differences between muscle-invasive and non-muscle-invasive bladder cancer, as it can affect the staging of the cancer.

For most JAK inhibitors dosing starts at the maximum safe dose, while ruxolitinib often requires lower initial doses and dose reductions over the first 12 weeks when cytopenias typically worsen before partially improving, warranting consideration of earlier switching to alternative JAK inhibitors instead of pushing through transfusions.

Reasons to switch JAK inhibitors include worsening blood counts and insufficient symptom or spleen response at maximum doses, with the goal of avoiding gaps in treatment by stopping one JAK inhibitor when ready to start the next to prevent symptom rebound while still allowing for potential increased efficacy from an alternative mechanism of action.

More facilitation is needed to ensure that clinicians can connect patients with breast cancer to clinical trials they may be eligible for.

An expert stressed the importance of finding a patient support group and asking questions after being diagnosed with kidney — or any other form — of cancer.

Response is assessed in patients starting a JAK inhibitor by monitoring symptoms on a severity scale, spleen size, blood counts, and overall patient impression of change, with the goal being reduction of symptoms and stabilization of blood counts to improve quality of life.

The JAK inhibitors approved for myelofibrosis have common side effects of cytopenias and gastrointestinal issues, with additional risks of weight gain and cardiac effects and diarrhea; momelotinib and pacritinib show improved tolerability compared to earlier JAK inhibitors.

An expert discusses the four FDA-approved JAK inhibitors for myelofibrosis - ruxolitinib, fedratinib, pacritinib, and momelotinib.